Alector's Rocky Road: Index Exit and Revised Targets Fuel Investor Debate
Alector (ALEC) faces a complex investor landscape following its removal from a key index and a mixed analyst update that raises its price target while maintaining a cautious rating, as the biotech firm grapples with significant projected revenue declines.